In this week's Pharma Pulse, Cencora agrees to acquire American Oncology Network, five major employers back electronic prior authorization for self-funded health plans and FDA finalizes its guidance on prescription drug apps and software.
Commentary|Podcasts|December 18, 2024
The Path Forward for Infused Biosimilars in the US
Author(s)Nicholas Saraceno, Senior Editor
Vibhu Tewary offers insight on this market segment, including a behind-the-scenes of what goes into designing a report.
Advertisement
In this exclusive PC Podcast interview, Vibhu Tewary, project director, IQVIA Institute for Human Data Science, discusses:
- Highlights of the company’s report surrounding the “Long-term Market Sustainability for Infused Biosimilars in the US: Foundational Analytics on Emerging Risks to Sustainability”
- The process that constructing and piecing together a report of this magnitude entails, along with where the idea itself came from
- The concept of net cost recovery
- The ongoing challenges surrounding ASP-based reimbursement
- A closed-door, multi-stakeholder virtual roundtable (based on his original report) that was previously held
The latest episode of The Pharmaceutical Commerce Podcast is available directly on
Advertisement
Related to this article
In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesalers.
In this week's Pharma Pulse, DHL adds six dedicated cold chain air corridors linking Europe and North America to Asia, Walmart rolls out a $0 prescription tier and rare disease Center of Excellence for its US workforce and FDA launches its Rare Disease Framework Initiative.
Jon Hamrick, partner at Curatio Advisors, discusses how product attributes, company size and stakeholder alignment shape pharma commercialization strategy.
The rule targets PBMs, but rebate, price protection and formulary deals they strike with drugmakers will be disclosed to plan fiduciaries and open to audit.
DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years beginning on or after July 1, 2027.
EVERSANA is folding Estima Scientific's AI-powered HEOR tools into its market access offerings as its CEO says evidence planning must start earlier.
Walgreens adds GLP-1 coverage navigation, Medicare Bridge support and pharmacist outreach to its virtual weight management service.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Pharma Pulse: GoodRx Opens Employer GLP-1 Channel, Lilly Fends Off Novo Ad Challenge, PCMA Takes Aim at Wholesalers
2
What DOL’s Final PBM Rule Means for Rebates and Formularies
3
Large Pharma vs. Emerging Biotech: Two Launch Playbooks
4
Q&A: Kerem Tokel on Pharma Cargo Theft Hotspots and the Shift to Outbound Diversion
5